ChEMBL


ChEMBL
ChEMBL
Chembl logo.png
Content
Description Biological database
Data types captured Molecules with drug-like properties and biological activity
Contact
Research center European Molecular Biology Laboratory
Laboratory United Kingdom European Bioinformatics Institute
Authors John Overington, Team Leader
Primary Citation PMID 21936816
Release date 2009
Access
Website ChEMBL
Download URL Downloads
Sparql endpoint SNORQL
Tools
Miscellaneous
License The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License
Versioning Chembl_11

ChEMBL or ChEMBLdb is a manually curated chemical database of bioactive molecules with drug-like properties.[1] It is maintained by the European Bioinformatics Institute (EBI), based on the Wellcome Trust Genome Campus, Hinxton, UK. The database, originally known as StARlite, was developed by a biotechnology company, Inpharmatica Ltd. latterly acquired by Galapagos NV. The data was acquired for EMBL in 2008 with an award from The Wellcome Trust, resulting in the creation of the ChEMBL chemogenomics group at EBI, led by John Overington.[2][3]

Contents

Scope and access

ChEMBL version 2 (ChEMBL_02) was launched in January 2010, including 2.4 million bioassay measurements covering 622,824 compounds, including 24,000 natural products. This was obtained from curating over 34,000 publications across twelve medicinal chemistry journals. ChEMBL's coverage of available bioactivity data has grown to become "the most comprehensive ever seen in a public database.".[2] In October 2010 ChEMBL version 8 (ChEMBL_08) was launched, with over 2.97 million bioassay measurements covering 636,269 compounds.[4]

ChEMBL_10 saw the addition of the PubChem confirmatory assays, in order to integrate data that is comparable to the type and class of data contained within ChEMBL.[5]

ChEMBLdb can be accessed via a web interface or downloaded by File Transfer Protocol. It is formated in a manner amenable to computerized data mining, and attempts to standardize activities between different publications, to enable comparative analysis.[1] ChEMBL is also integrated into other large-scale chemistry resources, including PubChem and the ChemSpider system of the Royal Society of Chemistry.

Associated resources

In addition to the database, the ChEMBL group have developed tools and resources for data mining.[6] These include Kinase SARfari, an integrated chemogenomics workbench focussed on kinases. The system incorporates and links sequence, structure, compounds and screening data. GPCR SARfari is a similar workbench focussed on GPCRs and ChEMBL-Neglected Tropical Diseases (ChEMBL-NTD) is a repository for Open Access primary screening and medicinal chemistry data directed at endemic tropical diseases of the developing regions of the Africa, Asia, and the Americas. The primary purpose of ChEMBL-NTD is to provide a freely accessible and permanent archive and distribution centre for deposited data.[2]

See also

References

  1. ^ a b Gaulton, A; et al. (2011). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Research. doi:10.1093/nar/gkr777. 
  2. ^ a b c Bender, A (2010). "Databases: Compound bioactivities go public". Nature Chemical Biology 309 (6). doi:10.1038/nchembio.354. http://www.nature.com/nchembio/journal/v6/n5/full/nchembio.354.html. Retrieved 2010-11-15. 
  3. ^ Overington J (April 2009). "ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr". J. Comput. Aided Mol. Des. 23 (4): 195–8. doi:10.1007/s10822-009-9260-9. PMID 19194660. 
  4. ^ ChEMBL-og (15 November 2010), ChEMBL_08 Released, http://chembl.blogspot.com/2010/11/chembl08-released.html, retrieved 2010-11-15 
  5. ^ ChEMBL-og (6 June 2011), ChEMBL_10 Released, http://chembl.blogspot.com/2011/06/chembl-10-released.html, retrieved 2011-06-09 
  6. ^ Bellis, L J; et al. (2011). "Collation and data-mining of literature bioactivity data for drug discovery.". Biochemical Society Transactions 39: 1365. doi:10.1042/BST0391365. http://www.biochemsoctrans.org/bst/039/bst0391365.htm. Retrieved 2011-24-09. 

External links



Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Druggability — is a term used in drug discovery to describe the suitability of a protein or protein complex to be targeted by a drug or drug like molecule, in a way that this interaction will alter the proteins function and correct disease causing behavior. The …   Wikipedia

  • Dabigatran — Systematic (IUPAC) name 3 ({2 [(4 Carbamimidoyl phenylamino) methyl] 1 methyl 1H benzoimidazole 5 carbonyl} pyridin 2 yl amino) propionic acid Clinical data …   Wikipedia

  • Хемоинформатика — Хемоинформатика  применение методов информатики для решения химических проблем. Сферы приложения хемоинформатики: прогноз физико химических свойств молекул (в частности, липофильности, водорастворимости), свойств материалов,… …   Википедия

  • Ammonia — For other uses, see Ammonia (disambiguation). Ammonia …   Wikipedia

  • Aspirin — Asprin redirects here. For the author, see Robert Asprin. Aspirin …   Wikipedia

  • Acetylene — HCCH redirects here. For other uses, see HCCH (disambiguation). Acetylene …   Wikipedia

  • Adenosine triphosphate — For the Japanese rock band, see Adenosine Tri Phosphate (band). Adenosine triphosphate …   Wikipedia

  • Ampicillin — Systematic (IUPAC) name (2S,5R,6R) 6 ([(2R) 2 amino 2 phenylace …   Wikipedia

  • Ascorbic acid — This article is about the molecular aspects of ascorbic acid. For information about its role in nutrition, see Vitamin C. L Ascorbic acid …   Wikipedia

  • Amphetamine — For other uses, see Amphetamine (disambiguation). Amphetamine Systematic (IUPAC) name …   Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.